Christophe Weber, Takeda CEO (Shoko Takayasu/Bloomberg via Getty Images)
Takeda reveals PhII fail for rare genetic condition, looks to new product pipeline to bolster growth
Takeda’s Phase II program in a rare hereditary disease called metachromatic leukodystrophy (MLD) is “likely to be discontinued” after failing its primary and secondary endpoints …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.